Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience

CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(04): 211-225
DOI: 10.4103/sajc.sajc_169_19

Letter to the Editor

Vikas T. Talreja

Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India

,

Vanita Noronha

Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India

,

Amit Joshi

Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India

,

Vijay Patil

Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India

,

Abhishek Mahajan

Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India

,

Kumar Prabhash

Department of Radiodiagnosis, Tata Memorial Hospital, Mumbai, Maharashtra, India

References
1 Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol 2018;36:2251-8.
2 Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study. Lancet Oncol 2018;19:1654-67. Erratum in: Lancet Oncol 2019;20:e10.